Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C21H23N3O5
CAS Number:
Molecular Weight:
397.42
MDL number:
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to pink
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
-10 to -25°C
SMILES string
N(O)C(=O)c1ccc(cc1)OCCNC(=O)c2[o]c3c(c2CN(C)C)cccc3, CN(C)CC1=C(C(NCCOC2=CC=C(C(NO)=O)C=C2)=O)OC3=CC=CC=C31
InChI
1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)
InChI key
MAUCONCHVWBMHK-UHFFFAOYSA-N
Biochem/physiol Actions
Orally bioavailable, potent and selective pan-HDAC inhibitor.
PCI-24781 (Abexinostat) is an orally bioavailable, potent, and selective pan-HDAC inhibitor that exhibits potent antitumor activities. It inhibits all Class I and Class II HDAC isoforms (Ki = 7 nM HDAC1, 19 nM HDAC2, 8.2 nM HDAC3/SMRT, 17 nM HDAC6, 280 nM HDAC8, 24 nM HDAC10) although it is reported to be a more potent inhibitor of HDACs 1 and 3 at low concentrations.
PCI-24781 (Abexinostat) is an orally bioavailable, potent, and selective pan-HDAC inhibitor that exhibits potent antitumor activities. It inhibits all Class I and Class II HDAC isoforms (Ki = 7 nM HDAC1, 19 nM HDAC2, 8.2 nM HDAC3/SMRT, 17 nM HDAC6, 280 nM HDAC8, 24 nM HDAC10) although it is reported to be a more potent inhibitor of HDACs 1 and 3 at low concentrations.
Storage Class
11 - Combustible Solids
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.